Clinical Trials Logo

Fecal Impaction clinical trials

View clinical trials related to Fecal Impaction.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02784093 Active, not recruiting - Fecal Impaction Clinical Trials

Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation

Start date: April 2015
Phase: Phase 2
Study type: Interventional

Fecal impaction (FI) is a common cause of lower gastrointestinal tract obstruction, and it is the result of chronic or severe constipation and most commonly found in the elderly population. Gastrografin is a water soluble contrast mediate that could act as an osmotic laxative. It has been shown to confer a therapeutic beneļ¬t in adhesive small bowel obstruction (SBO). The investigators speculate that gastrografin administrated orally may be more effective than enema in the treatment of fecal impaction induced intestinal obstruction.